INTRODUCTION {#sec0005}
============

Spinal Muscular Atrophy (SMA) is an autosomal recessive motor neuron disease manifested typically by infantile- or childhood-onset progressive muscle weakness. SMA is caused by degeneration of lower motor neurons in the spinal cord and brainstem. \[[@r1]\] Despite identification of a single mutation in the Survival Motor Neuron (SMN1) gene located on chromosome 5q13, SMA is phenotypically heterogeneous ranging from a life threatening to life altering disease due, in part, to a disease modifying homologue gene, SMN 2. The mild SMA phenotype, Type 3, also termed Kugelberg Welander disease, typically presents after age 18 months with symptoms of proximal muscle weakness, mostly involving the lower limbs. SMA Type 3 patients are able to walk unaided but have difficulty rising from the floor or low surfaces, running, and negotiating stairs. The muscle weakness is largely symmetrical and the severity of weakness is positively correlated with disease duration. \[[@r2]\]

SMA causes significant disability, and there is currently no effective drug treatment. Maximizing function, endurance, general health and well-being, in an effort to modulate disease morbidity, is the focus of supportive treatment modalities. In the general population, the benefits of exercise on long-term health and well-being are well established. \[[@r4]\] Despite promising pre-clinical and pilot reports, the effects of exercise in SMA have not been addressed in a controlled trial. Among healthy individuals as well as individuals with neuromuscular disorders, exercise has been shown to improve cardiorespiratory endurance, functional strength, and quality of life. \[[@r4]\] SMA 3 patients represent an ideal target population because their residual strength permits endurance and strengthening programs.

The overall goal of this project is to evaluate the effectiveness of aerobic and strengthening exercise to improve function in SMA, and to explore the physiology underlying the effects. Moreover, by studying the effects of exercise in human patients in a controlled trial, we hope to provide evidence for improved standard of care.

METHODS {#sec0010}
=======

Study design {#sec0015}
------------

This was an evaluator-blinded, randomized, controlled trial of aerobic and strengthening exercise in 14 ambulatory SMA patients ranging in age from 8 to 50 years. \[[@r11]\] The exercise protocol included an individualized muscle strengthening program in combination with a home based recumbent cycle ergometry aerobic exercise program. The aerobic exercise was performed five times weekly with target duration of 30 minutes per day. The strengthening exercise was performed three times weekly with a similar target duration. Patients were randomized either to an exercise arm or control arm after a one month lead in period. During months 2 to 7, the exercise group received the exercise intervention while the other group served as the control. The participants assigned to the control group were asked to continue their usual care during this period. After month 7, both groups received the exercise intervention. During the first 13 months of the study, participants were evaluated in-clinic every 3 months. Months 14 to 19 of the study were designed to mimic real-world conditions, during which time all participants were encouraged to continue on their own without formal monitoring or clinic visits, until month 19.

Study population {#sec0020}
----------------

All participants or guardians of participants signed informed consent approved by the Columbia University Medical Center Institutional Review Board. The study was registered with ClinicalTrials.gov (NCT01166022). The participant characteristics and performance on the outcome measures at baseline have been previously described \[[@r11]\] and are summarized below. There were more males than females enrolled. The age range was 10--48 years old. All of the patients in the exercise arm were described as having SMA type 3b, the milder phenotype of ambulatory SMA patients. In the control group, 4 patients had SMA type 3b and the other 3 had type 3a. At baseline, all participants had normal pulmonary function and substantially attenuated exercise capacity. On average, the exercise capacity was 35.3% of predicted for age and gender. Both groups were insufficiently active, spending on average 83.5% of waking hours in sedentary activities. The exercise and control groups were similar on all measured variables.

Intervention - cycle and strengthening {#sec0025}
--------------------------------------

The initial design of the exercise regimen was structured based on participant performance on the exercise tolerance test and strength assessments collected by the blinded evaluator according to widely accepted recommendations for exercise prescription. \[[@r12]\] Video-conferencing visits using Skype were utilized to ensure that the participants were performing the exercise correctly, to problem solve or change or advance their program according to their responses to exercise, and to enhance exercise safety and adherence. During these virtual visits, interim medical histories, concomitant medications and adverse events also were reviewed.

There were several different assessments incorporated in the study to measure participant adherence during the exercise intervention. These assessments included exercise diaries, heart rate monitors, and frequently scheduled electronic correspondence with the study team.

Outcome measures {#sec0030}
----------------

The primary outcome measure was distance walked during the six-minute walk test (6MWT). Percent-predicted distance on the six-minute walk test distance was computed from normative values. \[[@r13]\] Physiologic fatigue was determined by the difference in the distance walked in the first minute compared with the sixth minute and expressed as a percent, with a positive value representing fatigue. \[[@r15]\]

Secondary outcome measures {#sec0035}
--------------------------

Secondary outcomes included exercise capacity, strength and functional measures, quality of life and fatigue. Measurement of maximal oxygen uptake (VO2 max) is considered the gold standard measure of exercise tolerance. \[[@r16]\] Exercise tolerance is determined by the functioning of multiple body systems including cardiovascular, respiratory, and neuromuscular. \[[@r17]\] A limitation in one or more body systems will result in reduced exercise capacity, as identified in a lower than normal VO2 max. \[[@r17]\] Because maximal exercise testing including measurement of maximal oxygen uptake had not been administered previously to persons with SMA, the feasibility was uncertain at the start of the study.

Manual muscle testing (MMT) is performed as part of a routine neurological exam and is often included as a secondary outcome measure in clinical trials in neuromuscular disorders. We assessed 28 bilateral muscle groups of the arms and legs using MMT according to the Medical Research Council (MRC) 10-point grading scale. \[[@r18]\] Quantitative muscle strength assessments of 10 arm and leg muscle groups using a handheld dynamometer were also included.

Gross motor function was assessed using the Hammersmith Functional Motor Scale Expanded (HFMSE), \[[@r19]\] 10 meter walk /run, \[[@r15]\] and the Timed Up and Go Test (TUG). \[[@r20]\] Pulmonary function was assessed by measuring forced expiratory vital capacity (FVC) as percent predicted for age and height. \[[@r21]\]

Quality of life and fatigue {#sec0040}
---------------------------

Quality of life and perceived fatigue were captured at each visit using standard questionnaires. Child participants and parents were asked to complete the "PedsQL™ Generic Quality of Life Inventory" and "Multidimensional Fatigue Scale," a proprietary test, to measure quality of life and perceived fatigue. \[[@r22]\] The SF-36, a widely used health-related quality of life measure \[[@r23]\] and the Fatigue Severity Scale (FSS) a perceived fatigue severity questionnaire, \[[@r24]\] were completed by patients age 18 years and older.

Statistical methods {#sec0045}
-------------------

Efficacy was determined by comparing the mean difference in distance walked on the 6MWT over 6 months between the exercise and control group using an independent samples *t*-test. Similar analyses were performed on all other clinical variables collected. Repeated measures analyses of variance were used to evaluate the effects of exercise on the primary and secondary outcomes for all participants over 12 and 18 months in the control and exercise groups respectively. For all analyses, differences were considered statistically significant at alpha of *p*≤0.05.

RESULTS {#sec0050}
=======

Participant characteristics {#sec0055}
---------------------------

Twelve participants completed the first 7 months of the study, and 9 completed all 19 months. The two participants who dropped out during the first 7 months of the study lived more than 1,000 miles from the study site and found the travel too burdensome. One participant was enrolled in another clinical trial after completing the wait list control portion of the study and the other two participants completed at least 12 months of the study and chose not to continue during the unmonitored period. In general, participant compliance with the prescription was excellent based on patient diaries, interim Skype calls and clinic study visits. Most participants were at least 90% compliant with the exercise prescription over the 6 month intensive monitoring period of the study (*n* = 9).

Exercise ability, particularly aerobic exercise, improved slowly in the participants. Time spent during aerobic exercise was reported in the patient diaries and confirmed during video conferencing and in-person clinic visits. After 6 months, 50% of the participants had achieved the target volume of 150 minutes per week of aerobic exercise. The other participants' aerobic exercise intensity ranged from 24 -- 91 minutes per week at the same time point. Only one participant achieved 150 minutes of aerobic exercise per week at month 3. Strengthening exercise was reported in amount of time spent to perform the exercise and as the number of individual exercises completed. This was also included in the patient diaries and confirmed during video conferencing and in-person clinic visits. Unlike aerobic exercise, most patients reported performing all of the 5-6 strengthening exercises, for about 20--30 minutes, 3 times weekly as prescribed throughout the intervention period.

Exercise was well tolerated in all participants. Adverse events were collected during clinic and video-conferencing visits. An un-blinded study monitor reviewed reports monthly. All adverse events reported throughout the duration of the trial are included in [Table 1](#jnd-2-4-jnd150101-t001){ref-type="table"}. Migraine headaches were the most frequently reported other medical adverse event however all of the 25 events occurred in two participants with a history of this condition. Of the musculoskeletal events, falls were the most frequent, followed by musclesoreness and low back pain ([Table 1](#jnd-2-4-jnd150101-t001){ref-type="table"}). There were no group difference in the frequency of falls or muscle soreness, during the controlled period ([Table 2](#jnd-2-4-jnd150101-t002){ref-type="table"}). During the controlled period, low back pain was reported 5 times in one individual in the exercise group with a known history of this condition. Hip pain was reported only 3 times during the controlled period in one individual. The remaining musculoskeletal adverse events were reported infrequently over the entire 19 month study, occurring on 3 or less occasions, and therefore not included in a formal analysis. There were no study-related serious adverse events.

There were no significant group changes after 6 months in the primary outcome measure (distance walked on the 6MWT), or the measures of strength or motor function ([Table 3](#jnd-2-4-jnd150101-t003){ref-type="table"}). Similarly, there were no changes on any of the spatial or temporal gait variables collected during the 6MWT. Some but not all participants in the exercise arm showed improvements in function over 6 months ([Fig. 1](#jnd-2-4-jnd150101-g001){ref-type="fig"}). Although the changes were not statistically significant, all of these changes in the exercise arm were positive. Even with exercise over 12 and 18 months, there were no statistically significant changes on clinical measures of motor function and strength.

Participants performed an exercise tolerance test using an electronically-braked recumbent cycle ergometer. Oxygen uptake and related variables were measured during the test. All 14 subjects were able to complete the exercise tolerance test without injury or adverse events. The average VO2 max achieved was 15.16 mL/kg/min which is 34.1% of the predicted value for age and gender. Most patients (64% ) achieved maximal performance defined as a respiratory exchange ratio (RER) of \>1.

In all participants, there was a significant improvement in VO2 max within 6 months of exercise, and this improvement was even greater in the most compliant participants. These compliant participants were defined as those achieving 90% of the recommended exercise per week and not missing more than 2 weeks of exercise in a 3 month period. Percent-predicted VO2 max improved 4.9% in all participants (*p* = 0.036) (*n* = 10). Even greater changes (6.6% ) were seen in the most compliant participants (*p* = 0.012) (*n* = 5).

Quality of life and perceived fatigue {#sec0060}
-------------------------------------

Baseline comparisons between groups showed similar measures of quality of life and fatigue. \[[@r11]\] There were no significant changes in quality of life or perceived fatigue between or within the exercise and control groups over the 6 month control period or the duration of the study ([Table 4](#jnd-2-4-jnd150101-t004){ref-type="table"}).

DISCUSSION {#sec0065}
==========

Daily exercise, at a volume recommended for all Americans, including those with disability \[[@r25]\], appears to be safe in ambulatory SMA children and adults, and should be encouraged. Our study suggests that sustained aerobic exercise, at a volume recommended for healthy individuals, improves overall fitness in SMA patients. We did not uncover any deleterious effects on strength, function, or fatigue. All testing and intervention procedures were well tolerated without any serious adverse events.

Our study demonstrates that exercise performance in SMA improves very slowly, and this rate of change must be considered when designing timelines for future clinical trials. Despite eventually achieving the target exercise intensity, there were no significant changes in clinical measures of motor function and strength over the study duration. Similarly, there were no observed changes in perceived or physiologic fatigue in this study. Notably, our patients were able to maintain a regular, exercise regimen that met the U.S. targets for exercise without any adverse effects for up to 18 months, which would normally be expected to result in long-term general health benefits.

Although no significant improvements were observed in clinical measures of function and strength, modest benefits were achieved in aerobic capacity. However, when compared to other neuromuscular disorders undergoing similar training paradigms,SMA patients were less responsive to aerobic conditioning possibly representing an important clue to pathophysiological differences. Exercise capacity measured by peak oxygen uptake (VO2 max) appears to be lower in ambulatory SMA patients compared to other myopathic \[[@r5]\] and denervating disorders \[[@r26]\]. We speculate that this blunted response reflects an SMA specific mitochondrial dysfunction. In this study involving ambulatory SMA patients, baseline VO2 max ranged from 8.6 -- 25.1 mL/kg/min compared to a range of 17 -- 36 mL/kg/min found in adult populations with other neuromuscular conditions. Remarkably, comparable studies in most other disease groups reported significant positive training effects (up to 47% ) following 12 weeks of exercise using similar training protocols. \[[@r5]\]

In a recent open-label pilot study, SMA patients made improvements in aerobic capacity with 12 weeks of intensive exercise training, without concomitant improvements in strength and function. \[[@r28]\] This form of study design and treatment paradigm provides limited opportunity for gradual increases in exercise intensity and frequency. Unfortunately, for SMA patients, this intervention resulted in debilitating adverse effects such as complaints of overwhelming subjective fatigue, that made maintaining the exercise regimen difficult. \[[@r29]\] In our study in similar ambulatory SMA patients, we noted only modest improvements (6.6% ) in exercise capacity (V02 max) over 6 months even when the observations were limited to those patients who were considered compliant with the exercise prescription. Based on our clinical experience and these pilot studies, we believe SMA patients are vulnerable to incapacitating fatigue with overexertion. Maintaining a moderate level of exercise intensity and avoiding steep increases in activity in short time periods was thought to be sufficient to protect the SMA participants from this experience. Larger studies are necessary to determine the optimal titration of exercise dosing and explore relationships between slope of improvement in exercise ability and disease severity.

SMN is widely expressed in all tissues, yet the clinical phenotype associated with SMN deficiency is that of a motor neuron disease. It remains unclear why the alpha-motor neurons are unduly vulnerable. In fact, current evidence supports dysfunction of the sensory-motor spinal reflex circuit as a significant contributory disease mechanism. \[[@r30]\] Deficiency in transmission at the neuromuscular junction, \[[@r31]\] muscle, \[[@r32]\] as well as proprioceptive neurons and interneurons \[[@r30]\] in SMA confirms our understanding that SMA is not a cell autonomous disease and that structures other than motor neurons, in fact, contribute to the phenotype.

The apparent reduced oxidative capacity and blunted response to aerobic exercise training, observed in the patients enrolled in this study, may have genetic underpinnings. Our clinical findings may support the hypothesis that mitochondrial biogenesis is vulnerable to SMN insufficiency but further studies are necessary. In addition to the central role of mitochondria in motor neuron function, down-regulation of mitochondrial biogenesis has been suggested in SMA, \[[@r33]\] and other neurodegenerative disorders. \[[@r35]\] Muscle tissue from SMA patients showed reduced mitochondrial DNA content and reduced PGC1-alpha, the primary cofactor of mitochondrial biogenesis, and these findings were positively correlated with SMA disease severity. \[[@r34]\] We, therefore, speculate that impaired mitochondrial biogenesis is a downstream consequence of SMN insufficiency analogous to other recently reported downstream consequences of SMN insufficiency. \[[@r36]\] Hence, the clinical consequences of reduced mitochondrial biogenesis may account for the blunted response of SMA patients to aerobic conditioning exercise.

The results of this prospective, single (examiner) blinded, randomized and controlled clinical trial of the effect of exercise on established functional outcome measures provides important guidance to clinical management of SMA patients and future research study design. Moreover, the lack of observed improvement in functional measures and the blunted response in overall oxidative capacity suggests a new disease model that involves mitochondrial depletion throughout the whole motor unit. Weakness and fatigue, the clinical signatures of SMA, together with apparent reduced oxidative capacity, as documented in this study, suggest a vulnerability of mitochondrial biogenesis to SMN insufficiency and warrant further research.
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###### 

The frequency of all non-serious musculoskeletal and other adverse events reported from all participants (*n* = 14) during the entire study period

  Non-Serious Adverse Events                                   
  ---------------------------- --------- --------------------- ---------
  *Fall*                          156    *Migraine Headache*      25
  *Muscle Soreness*               18     *Fatigue*                10
  *Low Back Pain*                 11     *URI*                     8
  *Hip Pain*                       3     *Fever*                   4
  *Knee Pain*                      3     *Nasal Congestion*        3
  *Leg Weakness*                   2     *Paresthesia*             2
  *Neck/Shoulder Pain*             1     *Cough*                   2
  *Generalized Weakness*           1     *Ear Infection*           2
  *Upper Leg Pain*                 1     *Diarrhea*                1
  *Lower Leg Cramp*                1     *Sty (Right Eye)*         1
  *Arm Pain*                       1     *Sinus Infection*         1
  **Total**                     **198**  *Earache*                 1
                                         *Sore Throat*             1
                                         *Strep Throat*            1
                                         *Malaise*                 1
                                         *Ingrown Toenail*         1
                                         *Gastroenteritis*         1
                                         *CMV Infection*           1
                                         *Nosebleed*               1
                                         *Vertigo*                 1
                                         *Nausea*                  1
                                         *Elevated BP*             1
                                         *Influenza*               1
                                         **Total**              **71**
                                         **Overall Total**      **269**

###### 

Comparison of the frequency of non-serious musculoskeletal adverse events by group during the 6-month controlled period

  Adverse Event        Exercise   Control   *p*-value
  ------------------- ---------- --------- -----------
  *Fall*                  23        35        0.488
  *Muscle Soreness*       6          4        0.690

###### 

Comparisons of change in clinical outcome measures between the exercise and control groups over the 6-month controlled period

  Outcome Variable               Exercise (*n* = 5)   Control (*n* = 7)         *P*                          
  ----------------------------- -------------------- ------------------- ----------------- ----------------- -------
  6MWT Distance (m)                337.60 (81.46)      347.00 (79.00)     331.57 (133.00)   331.43 (111.96)   0.844
  Fatigue (% )                     21.82 (13.20)        21.80 (10.13)      25.99 (19.82)     24.53 (18.35)    0.791
  HFMSE                              50 (8.16)            52 (6.63)          54 (8.16)         54 (7.07)      0.357
  VO2Max (mL/kg/min)                12.72 (4.07)        12.60 (4.00)       15.94 (5.10)      14.60 (3.08)     0.496
  VO2Max (% predicted)              31.80 (5.97)        35.83 (5.07)       41.92 (12.22)     39.30 (7.92)     0.218
  10 meter walk/run (sec)           8.29 (2.62)          7.95 (2.61)        7.80 (3.00)       8.11 (2.72)     0.308
  TUG (sec)                         14.68 (6.25)        15.90 (8.23)       15.69 (17.47)     12.63 (9.76)     0.302
  Total MMT                        174.00 (18.40)      180.80 (21.37)     185.00 (33.40)    179.86 (32.69)    0.159
  Arm MMT                           76.40 (6.88)        81.20 (9.04)       78.71 (14.17)     76.00 (13.18)    0.080
  Leg MMT                          97.60 (12.24)        99.60 (15.90)     106.29 (22.33)    103.86 (21.86)    0.409
  HHD knee extension (kg)           4.44 (1.58)          3.54 (1.52)        2.33 (1.02)       2.16 (0.93)     0.560
  HHD knee flexion (kg)             6.64 (1.42)          5.34 (2.06)        4.71 (2.10)       4.20 (1.75)     0.340
  HHD shoulder abduction (kg)       3.48 (1.15)          3.02 (1.31)        4.06 (1.68)       4.00 (1.52)     0.165
  HHD elbow extension (kg)          2.90 (2.30)          2.86 (1.66)        3.99 (2.26)       3.66 (2.31)     0.485
  HHD elbow flexion (kg)            10.52 (4.40)         9.60 (5.71)       10.89 (4.90)      10.31 (4.47)     0.716
  FVC (% predicted)                103.20 (13.10)      104.00 (13.19)     102.86 (14.10)    101.43 (14.62)    0.476

Values are presented as mean (standard deviation) unless otherwise specified.6MWT = Six minute walk test. HFMSE = Hammersmith Functional Motor Scale Expanded, TUG = Timed Up and Go Test, MMT = Manual Muscle Testing using the Medical Research Council (MRC) 10-point grading scale. Total MMT = Total of all arm and leg muscle groups (28 groups). Maximum possible score = 280. Arm MMT = Total of all arm muscle groups from both arms (12 groups). Maximum possible score = 120. Leg MMT = Total of all leg muscle groups from both legs (16 groups). Maximum possible score = 160. HHD = Handheld dynamometry. FVC = Forced vital capacity.

###### 

Assessments of quality of life and perceived fatigue during the 6-month controlled period in **(A)** adult participants on the SF-36 and FSS, and **(B)** child participants and their parents on the PedsQL™ Neuromuscular and Fatigue Scales

  Outcome Variable      Exercise (*n* = 4)   Control (*n* = 2)                
  -------------------- -------------------- ------------------- ------------- -------------
  **(A)**                                                                     
  SF-36                                                                       
     Physical Health       35.6 (6.88)          36.1 (7.50)      39.4 (.29)    37.8 (1.60)
     Mental Health         60.3 (25.06)        60.5 (23.65)      54.2 (2.32)   55.0 (2.74)
                        Exercise (*n* = 4)   Control (*n* = 4)                
  FSS                       4.6 (1.69)          4.6 (1.51)        5.0 (.85)    5.4 (1.04)

Values are presented as mean (standard deviation) unless otherwise specified. SF-36 = Short Form 36. FSS = Fatigue Severity Scale.

  **(B)**                                                    
  ----------------------------- ------ ------ -------------- ---------------
  Neuromuscular (Peds QL)^\*^                                
     Child                       90.0   89.0   85.3 (13.61)    85.4 (9.40)
     Parent                      68.0   73.0   83.0 (10.81)    85.7 (9.61)
  Fatigue (Peds QL)^\*\*^                                    
     Child                       88.0   90.0   81.7 (15.49)   85.2 (12.12)
     Parent                      51.0   57.0   75.9 (18.86)   83.24 (14.43)

Values are presented as mean (standard deviation) unless otherwise specified. ^\*^PedsQL™ Quality of Life Neuromuscular Module. ^\*\*^PedsQL™ Multidimensional Fatigue Scale
